Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Are There Large Phase III Trials for Cannabis in OSA Treatment? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The study of cannabis for obstructive sleep apnoea (OSA)  has moved from early-stage trials into growing discussions about broader testing. However, the presence of Phase III trials for cannabis in OSA remains a key question in the medical research community. 

Am I eligible for medical cannabis for pain relief?

Current Research Landscape 

At present, most investigations have been limited to small pilot studies and Phase II experiments. The step towards Phase III trials for cannabis in OSA is crucial for validating results on a larger population. 

Large-Scale Trials 

Researchers emphasise that large-scale trials for cannabis are needed to provide conclusive safety and efficacy data. Without such studies, cannabis remains outside mainstream clinical guidelines for OSA. 

Clinical Development Pathway 

The clinical development in OSA requires carefully designed protocols, standardised dosing, and long-term monitoring. Progress towards Phase III trials for cannabis in OSA will depend on both funding and regulatory support. 

Barriers to Advancement 

While promising findings exist, challenges include regulatory restrictions and difficulties in recruiting patients for large-scale trials for cannabis. These hurdles delay progress towards definitive outcomes. 

Currently, there are no completed Phase III trials for cannabis in OSA, but scientific interest is growing. Moving from small studies to large-scale trials for cannabis is essential for advancing the clinical development in OSA and potentially shaping future treatment guidelines. 

If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea . 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories